72555 Metzingen, de
+47 (482) 52-584
Kitron signs a ten year agreement with DiaSorin's Irish branch
The duration of the signed agreement is 10 years and will have an annual volume of more than NOK 10 million. The manufacturing of DiaSorin's instruments like the LIAISON® IXT will take place at Kitron's factory in Arendal, Norway and deliveries will take place from Q2 2013.
Dag Songedal, Managing Director of Kitron AS declared: "Kitron is aiming to do business with the major players within our defined segments. DiaSorin is considered to be a global leading company within the In Vitro Diagnostics field. This cooperation will strengthen Kitron's position as one of Scandinavia's leading EMS companies."
Carlo Rosa, CEO of DiaSorin Group commented: "Kitron's expertise within EMS services including PCBAs, Box Build and High Level Assembly as well as their high ambition for world class quality, has been important for us when selecting a new partner".
Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. With their most recent acquisition of the NorDiag Group, DiaSorin gains access to the nucleic acid isolation and cell separation markets. Its line of products meets the clinical laboratory needs with flexibility in many clinical areas, such as infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market which identify DiaSorin Group as" the" in vitro diagnostics specialist. www.diasorin.com
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.